暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股期權個股詳情
ACAD240517P17000
- 1.85
- -0.02-1.07%
延時15分鐘行情交易中 05/14 09:45 (美東)
1.85最高價1.85最低價
1.85今開1.87昨收2張成交量8093張未平倉合約數17.00行權價370.00成交額101.92%引伸波幅-1.20%溢價2024/05/17到期日1.97内在价值100合約乘數3天距到期日0.00時間價值100合約規模美式期權類型-0.8787Delta0.1343Gamma6.99槓桿倍數-0.0387Theta-0.0012Rho-6.14有效槓桿0.0030Vega
分時
- 5日
- 日K
新聞
分析師提供有關醫療保健公司的見解：C4 Therapeutics（CCCC）、阿卡迪亞製藥（ACAD）和Disc Medicine（IRON）
坎託挑選了14只值得一看的被低估的生物技術股票
結果：阿卡迪亞製藥公司超出預期，共識已更新其估計
奧本海默將阿卡迪亞製藥的目標股價從19美元調整至17美元，維持業績評級
Capital IQ調查的分析師表示，阿卡迪亞製藥公司（ACAD）的平均評級爲跑贏大盤，目標股價在13美元至39美元之間。價格：15.45，漲幅：+0.24，變動百分比：+1
分析師對醫療保健公司發表見解：Intellia Therapeutics（NTLA）、Integer Holdings（ITGR）和阿卡迪亞製藥（ACAD）
B of A 證券將阿卡迪亞製藥維持在中性
B of A 證券將阿卡迪亞製藥維持在中性
評論
Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even 1
Several companies were in the spotlight due to various developments:
Oracle ( $甲骨文(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $阿卡迪亞(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$阿莎娜(ASAN.US$ Asana rep...
Oracle ( $甲骨文(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $阿卡迪亞(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$阿莎娜(ASAN.US$ Asana rep...
2
$阿卡迪亞(ACAD.US$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
1
6
閱讀更多